/images/ppid_59c68470-image-17854050403846156.webp)
What is the story about?
Ajanta Pharma Ltd
. reported a healthy set of June quarter earnings, with strong growth in its US generics business and steady performance across key domestic and international markets helping lift both revenue and profit. The company also rewarded shareholders with a generous interim dividend, while continuing to invest in research and product development.
Net profit for the quarter rose 30.9% year-on-year to ₹334.2 crore from ₹255.3 crore, while revenue increased 24.8% to ₹1,626 crore compared with ₹1,302.7 crore a year earlier.
Operating performance also remained strong. EBITDA climbed 20.6% to ₹423.6 crore from ₹351.4 crore in the corresponding quarter last year, although EBITDA margin eased marginally to 26.1% from 27% as the company continued to invest behind its growth initiatives.
The board declared the first interim dividend of ₹32 per equity share of face value ₹2 for FY27, amounting to a total payout of around ₹400 crore. August 5 has been fixed as the record date, with the dividend scheduled to be paid on or after August 18.
The standout performer during the quarter was the US generics business, where revenue surged 57% year-on-year to ₹487 crore. The Africa Institutional business also posted robust growth of 83%, while the Africa branded business expanded 30%.
India, Ajanta Pharma's largest branded generics market, delivered revenue growth of 24% to ₹509 crore. However, the Asia branded generics business remained the only weak spot, with revenue declining 16% year-on-year to ₹255 crore.
The company said its India branded generics business continued to outperform the broader pharmaceutical market. According to IQVIA MAT data for June 2026, Ajanta's branded generics business exceeded Indian Pharmaceutical Market (IPM) growth by 36%, aided by strong new product launches and volume expansion. New launches grew 76% faster than the IPM, while volume growth outpaced the market by 40%.
Ajanta Pharma also continued to strengthen its product pipeline. During the quarter, it received approval for three ANDAs, launched two products in the US market and increased its total commercialised ANDA portfolio to 51 products. Another 17 ANDAs remain pending approval with the US FDA, while five applications have received tentative approval.
The company spent ₹66 crore on research and development during the quarter, equivalent to around 4% of revenue, reflecting its continued focus on expanding its specialty and generics portfolio.
Following the earnings announcement, shares of Ajanta Pharma climbed to an intraday high of ₹3,531.90 before paring some gains to trade at ₹3,434.50, up 1.12%, on the NSE as of 2:57 PM.
Net profit for the quarter rose 30.9% year-on-year to ₹334.2 crore from ₹255.3 crore, while revenue increased 24.8% to ₹1,626 crore compared with ₹1,302.7 crore a year earlier.
Operating performance also remained strong. EBITDA climbed 20.6% to ₹423.6 crore from ₹351.4 crore in the corresponding quarter last year, although EBITDA margin eased marginally to 26.1% from 27% as the company continued to invest behind its growth initiatives.
The board declared the first interim dividend of ₹32 per equity share of face value ₹2 for FY27, amounting to a total payout of around ₹400 crore. August 5 has been fixed as the record date, with the dividend scheduled to be paid on or after August 18.
The standout performer during the quarter was the US generics business, where revenue surged 57% year-on-year to ₹487 crore. The Africa Institutional business also posted robust growth of 83%, while the Africa branded business expanded 30%.
India, Ajanta Pharma's largest branded generics market, delivered revenue growth of 24% to ₹509 crore. However, the Asia branded generics business remained the only weak spot, with revenue declining 16% year-on-year to ₹255 crore.
The company said its India branded generics business continued to outperform the broader pharmaceutical market. According to IQVIA MAT data for June 2026, Ajanta's branded generics business exceeded Indian Pharmaceutical Market (IPM) growth by 36%, aided by strong new product launches and volume expansion. New launches grew 76% faster than the IPM, while volume growth outpaced the market by 40%.
Ajanta Pharma also continued to strengthen its product pipeline. During the quarter, it received approval for three ANDAs, launched two products in the US market and increased its total commercialised ANDA portfolio to 51 products. Another 17 ANDAs remain pending approval with the US FDA, while five applications have received tentative approval.
The company spent ₹66 crore on research and development during the quarter, equivalent to around 4% of revenue, reflecting its continued focus on expanding its specialty and generics portfolio.
Following the earnings announcement, shares of Ajanta Pharma climbed to an intraday high of ₹3,531.90 before paring some gains to trade at ₹3,434.50, up 1.12%, on the NSE as of 2:57 PM.
/images/ppid_59c68470-image-178557758077455130.webp)
